Literature DB >> 23338774

Extent of resection and radiotherapy in GBM: A 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients.

Pascal O Zinn1, Rivka R Colen, Ekkehard M Kasper, Jan-Karl Burkhardt.   

Abstract

Surgery, radiation and chemotherapy are the standard of care for GBM patients, however, the impact of extent of resection (EOR) and radiotherapy (RT) on patient survival across age groups has not been established. Therefore, we present the current largest study on EOR and RT in GBM over the past three decades. Using the population based Surveillance, Epidemiology and End Results (SEER) registry, we identified a total of 21,783 GBM patients (1973-2007). Survival analysis based on EOR and RT was performed by means of factor analysis, Kaplan-Meier survival and Cox proportional hazard's ratio. Age, RT and EOR were highly prognostic (p<0.00001). Combined gross total resection (GTR) and RT showed the longest median survival (11 months) compared to subtotal resection (STR) and RT (9 months). Survival times after monotherapy with RT, GTR and STR were 5, 3 and 2 months, respectively. Patients without therapy showed a median survival of 1 month. RT and GTR demonstrated highest median survival. Interestingly, survival advantage of GTR versus STR amounted to only 1-2 months. Monotherapy (GTR, STR or RT) showed a significantly lower survival rate compared to combination therapies. RT alone yielded significantly better survival compared to any resective approach. Relative to overall age-specific median survival, elderly patients still reasonably benefit from RT alone. However, across all age groups multimodality treatment with surgery and RT continues to provide the largest survival benefit compared to either treatment alone and, thus, should be pursued whenever feasible.

Entities:  

Mesh:

Year:  2013        PMID: 23338774     DOI: 10.3892/ijo.2013.1770

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  30 in total

Review 1.  Optimizing glioblastoma resection: intraoperative mapping and beyond.

Authors:  Joseph A Osorio; Manish K Aghi
Journal:  CNS Oncol       Date:  2014

2.  Blood-Based Biomarkers in High Grade Gliomas: a Systematic Review.

Authors:  Daniela Pierscianek; Yahya Ahmadipour; Marvin Darkwah Oppong; Laurèl Rauschenbach; Sied Kebir; Martin Glas; Ulrich Sure; Ramazan Jabbarli
Journal:  Mol Neurobiol       Date:  2019-02-04       Impact factor: 5.590

3.  The influence of intraoperative resection control modalities on survival following gross total resection of glioblastoma.

Authors:  Marian C Neidert; Isabel C Hostettler; Jan-Karl Burkhardt; Malte Mohme; Ulrike Held; Reto Kofmehl; Günter Eisele; Christoph M Woernle; Luca Regli; Oliver Bozinov
Journal:  Neurosurg Rev       Date:  2016-02-09       Impact factor: 3.042

4.  Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Authors:  Benjamin M Ellingson; Lauren E Abrey; Sarah J Nelson; Timothy J Kaufmann; Josep Garcia; Olivier Chinot; Frank Saran; Ryo Nishikawa; Roger Henriksson; Warren P Mason; Wolfgang Wick; Nicholas Butowski; Keith L Ligon; Elizabeth R Gerstner; Howard Colman; John de Groot; Susan Chang; Ingo Mellinghoff; Robert J Young; Brian M Alexander; Rivka Colen; Jennie W Taylor; Isabel Arrillaga-Romany; Arnav Mehta; Raymond Y Huang; Whitney B Pope; David Reardon; Tracy Batchelor; Michael Prados; Evanthia Galanis; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-08-02       Impact factor: 12.300

Review 5.  Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

Review 6.  Rare case of radiation-induced trigeminal schwannoma occurring in a long-term glioblastoma multiforme survivor.

Authors:  Mina Al Shalchi; Shaila Hussain; Selvaraj Giridharan; Erminia Albanese
Journal:  BMJ Case Rep       Date:  2016-03-11

7.  Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma.

Authors:  Ryan Rhome; Rebecca Fisher; Adília Hormigo; Rahul R Parikh
Journal:  J Neurooncol       Date:  2016-03-12       Impact factor: 4.130

8.  The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

Authors:  Remco J Molenaar; Dagmar Verbaan; Simona Lamba; Carlo Zanon; Judith W M Jeuken; Sandra H E Boots-Sprenger; Pieter Wesseling; Theo J M Hulsebos; Dirk Troost; Angela A van Tilborg; Sieger Leenstra; W Peter Vandertop; Alberto Bardelli; Cornelis J F van Noorden; Fonnet E Bleeker
Journal:  Neuro Oncol       Date:  2014-02-06       Impact factor: 12.300

9.  LncRNA MATN1-AS1 prevents glioblastoma cell from proliferation and invasion via RELA regulation and MAPK signaling pathway.

Authors:  Na Han; Li Yang; Xiaoxi Zhang; Yangmei Zhou; Rui Chen; Yang Yu; Zhen Dong; Mengxian Zhang
Journal:  Ann Transl Med       Date:  2019-12

Review 10.  Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis.

Authors:  Timothy J Brown; Matthew C Brennan; Michael Li; Ephraim W Church; Nicholas J Brandmeir; Kevin L Rakszawski; Akshal S Patel; Elias B Rizk; Dima Suki; Raymond Sawaya; Michael Glantz
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.